Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Generics group Alvogen puts Eastern European operations up for sale - sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/20/2018 | 04:47pm CEST
FILE PHOTO: Pharmaceutical tablets and capsules in blister packs are arranged on table in illustration picture in Ljubljana

FRANKFURT (Reuters) - Generics firm Alvogen is putting its Central and Eastern European (CEE) operations up for sale as its private equity owners seek a step-by-step exit from the maker of drugs against cancer, heart and lung diseases, people close to the matter said.

Buyout group CVC and Singapore state fund Temasek, which bought a controlling stake in Alvogen in 2015 at a valuation of $2 billion, have asked investment bank Jefferies to find a buyer for Alvogen's CEE business, which may be valued at up to $1 billion, they added.

CVC and Jefferies declined to comment, Temasek was not immediately available for comment.

A sale of the operations would come amid a flurry of other generics company deals.

Buyout group Advent earlier this week bought Sanofi Zentiva unit, beating groups such as Carlyle, BC Partners, Blackstone, Nordic Capital, as well as Brazilian drugs firm EMS and India's Torrent Pharma.

Bain and Cinven last year acquired Germany's Stada, beating rivals Advent and Permira.

Separately, Novartis is considering a sale of its generics business, people familiar with the matter have said.

While Alvogen's owners have not begun an official auction, they have started reaching out to the firms that showed an interest in Stada and Zentiva.

"The private equity owners of these companies have said that they want to use the platforms to build strong generics players, so most of the groups which showed an interest in Zentiva and Stada are expected to raise their hands for Alvogen's Eastern European ops," one of the sources said.

Alvogen was founded in 2009 by former Actavis Chief Executive Robert Wessman, who has since built it into a maker of generics, over-the counter and biosimilar drugs with operations in 35 countries, employing 2,800 staff.

In Central and Eastern Europe, Alvogen has manufacturing facilities in Romania and a packaging centre in Serbia serving the entire region.

Last year, Alvogen's controlling shareholders held talks with Shanghai Pharmaceuticals over the sale of Alvogen's U.S. business, according to media reports, but no deal materialised.

(Additional reporting by Ben Martin; Editing by Mark Potter)

By Arno Schuetze and Pamela Barbaglia

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS -1.55% 76.08 Delayed Quote.-7.67%
SANOFI -0.49% 65.28 Real-time Quote.-9.14%
SHANGHAI PHARMACEUTICALS HOLDING CO LTD -1.52% 22.65 End-of-day quote.-6.37%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
04/20Generics group Alvogen puts Eastern European operations up for sale - sources
RE
04/20NOVARTIS : renews commitment to malaria elimination, investing USD 100 million t..
AQ
04/20AVEXIS : Novartis tender offer for AveXis commences
AQ
04/20AMGEN : Novartis presents first-of-its-kind evidence at AAN reinforcing robust a..
AQ
04/20NOVARTIS : Jay Bradner bemoans `redundant investment in the biotech sector` for ..
AQ
04/20NOVARTIS : Surface slips in first trading day
AQ
04/20NOVARTIS : New Novartis analyses at AAN show siponimod's efficacy on disability ..
GL
04/19NOVARTIS : Patent Issued for Brake System (USPTO 9939603)
AQ
04/19NOVARTIS : Patent Issued for Adjusting Laser Treatment in Response to Changes in..
AQ
04/19NOVARTIS : Sandoz signs agreement with Pear Therapeutics to develop and commerci..
AQ
More news
News from SeekingAlpha
04/20WALL STREET BREAKFAST, APRIL 20TH : Tough Trade Talk With China And Canada, Russ.. 
04/20YOUR DAILY PHARMA SCOOP : Adamas Update, Shire Bidding War, Novartis Results 
04/20WALL STREET BREAKFAST : Spring Meetings For IMF, World Bank 
04/19Novartis AG (NVS) Q1 2018 Results - Earnings Call Transcript 
04/19Novartis AG 2018 Q1 - Results - Earnings Call Slides 
Financials ($)
Sales 2018 52 460 M
EBIT 2018 12 808 M
Net income 2018 9 186 M
Debt 2018 14 590 M
Yield 2018 3,82%
P/E ratio 2018 16,25
P/E ratio 2019 19,04
EV / Sales 2018 4,19x
EV / Sales 2019 4,02x
Capitalization 205 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 92,3 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
Srikant Madhav Datar Independent Non-Executive Director
Andreas von Planta Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-7.67%204 972
JOHNSON & JOHNSON-8.71%342 627
PFIZER1.13%217 064
ROCHE HOLDING LTD.-12.17%193 713
MERCK AND COMPANY4.55%158 813
AMGEN-1.35%117 021